Automated production of CCR5-negative CD4
Journal
Gene therapy
ISSN: 1476-5462
Titre abrégé: Gene Ther
Pays: England
ID NLM: 9421525
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
13
10
2020
accepted:
01
04
2021
revised:
22
03
2021
pubmed:
20
4
2021
medline:
28
10
2021
entrez:
19
4
2021
Statut:
ppublish
Résumé
Ex-vivo gene editing in T lymphocytes paves the way for novel concepts of immunotherapy. One of those strategies is directed at the protection of CD4
Identifiants
pubmed: 33867524
doi: 10.1038/s41434-021-00259-5
pii: 10.1038/s41434-021-00259-5
pmc: PMC8455337
doi:
Substances chimiques
CCR5 protein, human
0
Receptors, CCR5
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
572-587Informations de copyright
© 2021. The Author(s).
Références
Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370:901–10.
pubmed: 24597865
pmcid: 4084652
doi: 10.1056/NEJMoa1300662
Deng HK, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661–6.
pubmed: 8649511
doi: 10.1038/381661a0
Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4
pubmed: 8649512
doi: 10.1038/381667a0
Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.
pubmed: 8756719
doi: 10.1016/S0092-8674(00)80110-5
Paxton WA, Martin SR, Tse D, O’Brien TR, Skurnick J, VanDevanter NL, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat Med. 1996;2:412–7.
pubmed: 8597950
doi: 10.1038/nm0496-412
Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, Allers K, et al. Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. N Engl J Med. 2009;360:692–7.
pubmed: 19213682
doi: 10.1056/NEJMoa0802905
Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019;568:244–8.
pubmed: 30836379
pmcid: 7275870
doi: 10.1038/s41586-019-1027-4
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.
pubmed: 17115046
doi: 10.1038/nm1511
Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4
pubmed: 12721933
doi: 10.1086/374786
Zeng M, Southern PJ, Reilly CS, Beilman GJ, Chipman JG, Schacker TW, et al. Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. 2012;8:e1002437.
pubmed: 22241988
pmcid: 3252371
doi: 10.1371/journal.ppat.1002437
Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, et al. A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infect Dis Ther. 2018;7:183–95.
pubmed: 29761330
pmcid: 5986685
doi: 10.1007/s40121-018-0201-6
Morgan RA. Gene therapy for HIV infection. Clin Exp Immunol. 1997;107:41–4.
pubmed: 9020935
Hildinger M, Dittmar MT, Schult-Dietrich P, Fehse B, Schnierle BS, Thaler S, et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol. 2001;75:3038–42.
pubmed: 11222732
pmcid: 115933
doi: 10.1128/JVI.75.6.3038-3042.2001
Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, et al. Preferential survival of CD4
pubmed: 16149905
doi: 10.1089/hum.2005.16.1065
van Lunzen J, Glaunsinger T, Stahmer I, von Baehr V, Baum C, Schilz A, et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther. 2007;15:1024–33.
pubmed: 17356541
doi: 10.1038/mt.sj.6300124
Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P, et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood. 1999;94:368–71.
pubmed: 10381536
doi: 10.1182/blood.V94.1.368.413a47_368_371
Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, Cole S, et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther. 2004;15:251–62.
pubmed: 15018734
doi: 10.1089/104303404322886101
Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, et al. Establishment of HIV-1 resistance in CD4
pubmed: 18587387
pmcid: 3422503
doi: 10.1038/nbt1410
Mussolino C, Morbitzer R, Lütge F, Dannemann N, Lahaye T, Cathomen T. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 2011;39:9283–93.
pubmed: 21813459
pmcid: 3241638
doi: 10.1093/nar/gkr597
Xu L, Wang J, Liu Y, Xie L, Su B, Mou D, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med. 2019;381:1240–7.
pubmed: 31509667
doi: 10.1056/NEJMoa1817426
Karpinski J, Hauber I, Chemnitz J, Schäfer C, Paszkowski-Rogacz M, Chakraborty D, et al. Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol. 2016;34:401–9.
pubmed: 26900663
doi: 10.1038/nbt.3467
Chung CH, Allen AG, Atkins AJ, Sullivan NT, Homan G, Costello R, et al. Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-κB Binding Sites. Mol Ther — Nucleic Acids. 2020;4:965–82.
doi: 10.1016/j.omtn.2020.07.016
Mock U, Riecken K, Berdien B, Qasim W, Chan E, Cathomen T, et al. Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. Sci Rep. 2014;4:6409.
pubmed: 25230987
pmcid: 4166709
doi: 10.1038/srep06409
Mock U, Machowicz R, Hauber I, Horn S, Abramowski P, Berdien B, et al. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res. 2015;43:5560–71.
pubmed: 25964300
pmcid: 4477672
doi: 10.1093/nar/gkv469
Schwarze LI, Głów D, Sonntag T, Uhde A, Fehse B. Optimisation of a TALE nuclease targeting the HIV coreceptor CCR5 for clinical application. Gene Ther.:contemporaneously submitted.
Fine EJ, Cradick TJ, Zhao CL, Lin Y, Bao G. An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids Res. 2014;42:1–13.
doi: 10.1093/nar/gkt1326
Doyle EL, Booher NJ, Standage DS, Voytas DF, Brendel VP, VanDyk JK, et al. TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: Tools for TAL effector design and target prediction. Nucleic Acids Res. 2012;40:117–22.
doi: 10.1093/nar/gks608
Mock U, Hauber I, Fehse B. Digital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleases. Nat Protoc. 2016;11:598–615.
pubmed: 26914317
doi: 10.1038/nprot.2016.027
Cornils K, Thielecke L, Hüser S, Forgber M, Thomaschewski M, Kleist N, et al. Multiplexing clonality: combining RGB marking and genetic barcoding. Nucleic Acids Res. 2014;42:1–10.
doi: 10.1093/nar/gku081
Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel lentiviral “gene ontology” (LeGO) vectors for functional gene analysis. Mol Ther. 2008;16:698–706.
pubmed: 18362927
doi: 10.1038/mt.2008.6
Mock U, Thiele R, Uhde A, Fehse B, Horn S. Efficient Lentiviral Transduction and Transgene Expression in Primary Human B Cells. Hum Gene Ther Methods. 2012;23:408–15
pubmed: 23240650
doi: 10.1089/hgtb.2012.160
Berdien B, Mock U, Atanackovic D, Fehse B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 2014;21:539–48.
pubmed: 24670996
doi: 10.1038/gt.2014.26
Gundry CN, Vandersteen JG, Reed GH, Pryor RJ, Chen J, Wittwer CT. Amplicon melting analysis with labeled primers: A closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem. 2003;49:396–406.
pubmed: 12600951
doi: 10.1373/49.3.396
Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem. 2003;49:853–60.
pubmed: 12765979
doi: 10.1373/49.6.853
Thomas HR, Percival SM, Yoder BK, Parant JM. High-throughput genome editing and phenotyping facilitated by high resolution melting curve analysis. PLoS ONE. 2014;9:e114632
Zhou Y, Maldini CR, Jadlowsky J, Riley JL. Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. J Infect Dis. 2021;223:S38–45.
doi: 10.1093/infdis/jiaa223
pmcid: 7883023
Wang J, Holmes MC. Engineering hematopoietic stem cells toward a functional cure of human immunodeficiency virus infection. Cytotherapy. 2016;18:1370–81.
pubmed: 27745602
doi: 10.1016/j.jcyt.2016.07.007
Leibman RS, Riley JL. Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther. 2015;23:1149–59.
pubmed: 25896251
pmcid: 4817793
doi: 10.1038/mt.2015.70
Peterson CW, Kiem HP. Cell and Gene Therapy for HIV Cure. Curr Top Microbiol Immunol. 2018;417:211–48.
pubmed: 29256135
Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, Hartmann M, et al. Resistance of mature T cells to oncogene transformation. Blood. 2008;112:2278–86.
pubmed: 18566328
doi: 10.1182/blood-2007-12-128751
Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 2003;101:2563–9.
pubmed: 12456496
doi: 10.1182/blood-2002-09-2800
Priesner C, Aleksandrova K, Esser R, Mockel-Tenbrinck N, Leise J, Drechsel K, et al. Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+ T Cells for Manufacturing of Gene Therapy Medicinal Products. Hum Gene Ther. 2016;27:860–9.
pubmed: 27562135
pmcid: 5035932
doi: 10.1089/hum.2016.091
Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, et al. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. Hum Gene Ther. 2017;28:914–25.
pubmed: 28847167
doi: 10.1089/hum.2017.111
Morales JMM, Münch N, Peter K, Freund D, Oelschlägel U, Höllig K et al. Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System. Front Immunol. 2019;10:1–10.
Aleksandrova K, Leise J, Priesner C, Melk A, Kubaink F, Abken H, et al. Functionality and Cell Senescence of CD4 / CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy ® Platform. Transfus Med Hemother. 2019;46:47–54.
Tittlbach H, Schneider A, Strobel J, Zimmermann R, Maas S, Gebhardt B, et al. GMP-production of purified human B lymphocytes for the adoptive transfer in patients after allogeneic hematopoietic stem cell transplantation. J Transl Med. 2017;15:1–11.
doi: 10.1186/s12967-017-1330-5
Skorska A, Müller P, Gaebel R, Große J, Lemcke H, Lux CA, et al. GMP-conformant on-site manufacturing of a CD133+ stem cell product for cardiovascular regeneration. Stem Cell Res Ther. 2017;8:1–15.
doi: 10.1186/s13287-016-0467-0
Stewart SJ, Fujimoto J, Levy R. Human T lymphocytes and monocytes bear the same Leu-3(T4) antigen. J Immunol. 1986;136:3773 LP–3778.
doi: 10.4049/jimmunol.136.10.3773
Zhen A, Krutzik SR, Levin BR, Kasparian S, Zack JA, Kitchen SG. CD4 Ligation on Human Blood Monocytes Triggers Macrophage Differentiation and Enhances HIV Infection. J Virol. 2014;88:9934–46.
pubmed: 24942581
pmcid: 4136363
doi: 10.1128/JVI.00616-14
Jackson Z, Roe A, Sharma AA, Pereira Lopes FBT, Talla A, Kleinsorge-Block S, et al. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma. Front Immunol. 2020;11:1–13.
Fernández L, Fernández A, Mirones I, Escudero A, Cardoso L, Vela M, et al. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy. Front Immunol. 2019;10:1–12.
doi: 10.3389/fimmu.2019.02361
Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, et al. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018;20:394–406.
pubmed: 29287970
doi: 10.1016/j.jcyt.2017.09.005
Mock U, Nickolay L, Philip B, Cheung GWK, Zhan H, Johnston ICD, et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy. 2016;18:1002–11.
pubmed: 27378344
doi: 10.1016/j.jcyt.2016.05.009
Rust BJ, Kiem HP, Uldrick TS. CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies. Lancet Haematol. 2020;7:e690–6.
pubmed: 32791043
doi: 10.1016/S2352-3026(20)30142-3